Target-based anti-angiogenic therapy in breast cancer

Current Pharmaceutical Design

Volumn 18, Issue 27, 2012, Pages 4244-4257

  Wehland, Markus ^a   Bauer, Johann ^b   Infanger, Manfred ^a   Grimm, Daniela ^a,c  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Angiogenesis; Breast cancer; Neoangiogenesis inhibition; Tyrosine kinase inhibitor; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; ANASTROZOLE; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CTCE 9908; DOCETAXEL; ELLAGIC ACID; EVEROLIMUS; FULVESTRANT; LAPATINIB; LETROZOLE; NAVELBINE; NERVE GROWTH FACTOR; PACLITAXEL; PAZOPANIB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANOREXIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DYSGEUSIA; FATIGUE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERURICEMIA; MONOTHERAPY; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOSIS; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL RATE;

EID: 84866318108     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802430468     Document Type: Review

References (171)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 03/24/2012.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
4. Herschkowitz J, Simin K, Weigman V, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
5. Prat A, Parker J, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
6. Millikan R, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-39.
7. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
8. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
9. Hu Z, Cheng F, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
10. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer. Clin Cancer Rev. 2010; 16: 5222-32.
11. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-67
12. Hugh J, Hanson J, Cheang MCU, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-76.
13. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-34.
14. Rouzier R, Perou C, Symmans W, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-85.
15. Grimm D, Wehland M, Pietsch J, Infanger M, Bauer J. Drugs interfering with apoptosis in breast cancer. Curr Pharm Des 2011; 17: 272-83
16. Grimm D, Bauer J, Schoenberger J. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases. Curr Vasc Pharmacol 2009; 7(3): 347-57.
17. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004; 1(1): 39-43.
18. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009; 23(5): 289-304.
19. Zhu Z, Hattori K, Zhang H, et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 2003; 17:604-11.
20. Grimm D, Bauer J, Pietsch J, et al. Diagnostic and Therapeutic Use of Membrane Proteins in Cancer Cells. Curr Med Chem 2011; 18: 176-90.
21. Schoenberger J, Grimm D, Kossmehl P, et al. Effects of PTK787/ZK222584 a tyrosine kinase inhibitor on the growth of a poorly differentiated thyroid carcinoma.An animal study. Endocrinology 2004; 145: 1031-8.
22. Straume O, Chappuis PO, Salvesen HB, et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 2002; 62: 6808-11.
23. Fox SB, Gatter KC, Bicknell R, et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53: 9161-63.
24. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. Cancer Res 1999; 59: 5602-7.
25. Kakolyris S, Fox SB, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000; 82: 844-51.
26. Shirakawa K, Wakasugi H, Heike Y, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99: 821-8.
27. Arnold F, West DC. Angiogenesis in wound healing. Pharmacol Ther 1991; 52: 407-22.
28. Reynolds LP, Redmer DA, Angiogenesis in the placenta. Biol. Reprod 2001; 64: 1033-40.
29. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
30. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64.
31. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-7.
32. Sullivan, R., Graham, C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007; 26 (2): 319-31.
33. Ferrara N. Role of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001; 280(6): C1358-66.
34. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9: 666-9.
35. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550-63.
36. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12: 5018-22.
37. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res 2008; 102: 637-52.
38. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
39. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF(164) and VEGF(188). Nature Med 1999; 5: 495-502.
40. Xiong S, Grijalva R, Zhang LL, et al. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulinbeta 1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res 2001; 61: 1727-32.
41. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-90.
42. Kawai H, Li HC, Chun P, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 2002; 21: 7730-39.
43. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Rev Oncol Hematol 2007; 62: 179-213.
44. Ruohola JK, Valve EM, Karkkainen MJ, et al. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 1999; 1499: 29-40.
45. Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer - Tumor promoting effects of transforming growth factor-beta. Breast Cancer Res 2000; 2: 125-32.
46. McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996; 98: 482-9.
47. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006; 168(2): 639-48.
48. Grützkau A, Krüger-Krasagakes S, Baumeister H, et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell. 1998; 9(4): 875-84.
49. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol. 2011; 55(3): 261-8.
50. Möhle R, Green D, Moore MA, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997; 94(2): 663-8.
51. Elias I, Franckhauser S, Ferré T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against dietinduced obesity and insulin resistance. Diabetes. 2012 Apr 20. [Epub ahead of print]
52. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
53. Dor Y, Porat R, Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001; 280(6): C1367-C1374.
54. Infanger M, Faramarzi S, Grosse J, et al. Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol 2007; 16(5): 291-299.
55. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64(5/6): 993-8.
56. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18(1): 4-25.
57. Herbert SP, Stainier DYR. Molecular control of endothelial cell behavior during blood vessel morphogenesis. Nature Rev 2011; 12: 551-564.
58. Red-Horse K, Crawford Y, Shojaei F, Ferrara N. Endotheliummicroenvironment interactions in the developing embryo and in the adult. Dev Cell 2007; 12: 181-194.
59. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrixbound VEGF. Mol Biol Cell. 1993; 4(12): 1317-1326.
60. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991; 5: 1806-1814.
61. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266: 11947-11954.
62. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
63. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-26037.
64. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-7795.
65. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulatesbioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-691.
66. Zhang HT, Scott PA, Morbidelli L, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83: 63-68.
67. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
68. Terman BI, Carrion ME, Kovacs E, Rasmussen BA, Eddy RL, Shows TB. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-1683.
69. Karkkainen MJ, Mäkinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol. 2002; 4: E2-E5.
70. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25(4): 581-611.
71. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005, 438: 946-53.
72. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005; 109: 227-241.
73. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
74. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelialgrowth factor bioactivity, in vitro and in vivo, and high affinitybinding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
75. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 4: 9349-9354.
76. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
77. Plouet J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989; 8: 3801-3808.
78. Infanger M, Shakibaei M, Kossmehl P, et al. Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model. J Vasc Res 2005; 42: 202-2013.
79. Infanger M, Grosse J, Westphal K, et al. Vascular Endothelial Growth Factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann Vasc Surg 2008; 22: 273-284.
80. Infanger M, Schmidt O, Kossmehl P, et al. Vascular endothelial growth factor serum level is strongly enhanced after burn injury and correlated with local and general tissue edema. Burns 2004; 30: 305-311.
81. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-1028.
82. Gerber HP, Dixit V, Ferrara N. Vascular Endothelial Growth Factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-13316.
83. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
84. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
85. Infanger M, Kossmehl P, Shakibaei M, et al. Induction of threedimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity. Impact of vascular endothelial growth factor. Apoptosis 2006; 11:749-764.
86. Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol 1995; 62: 203-215.
87. http://www.clinicaltrials.gov/, last accessed 05/22/2012
88. Jones A, Ellis P. Potential withdrawal of bevacizumab for the treatment of breast cancer. BMJ. 2011; 343: d4946
89. Ferrara N, Hillan K, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-398.
90. Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12: 3124-3129.
91. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28:1779-1802.
92. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 117-124.
93. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
94. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
95. Miles DW, Chan A, Dirix LY, et al. Phase III study of Bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247.
96. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double blind, placebo-controlled, phase III trial of chemotherapy with or without Bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
97. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-Negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-4293.
98. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:15s, 2010 (suppl; abstr 1005)
99. Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010; 122: 1-7.
100. Cuppone F, Bria E, Vaccaro V, et al. Magnitude of risks and benefits of the addition of Bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011; 30: 54.
101. http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf, last accessed on 04/24/2012
102. Hobday TJ, Rowland K, Dueck A, et al. N0537: a North Central Cancer Treatment Group (NCCTG) phase II study of VEGF Trap in patients with metastatic breast cancer previously treated with anthracycline and/or taxanes [abstract]. 2008 Breast Cancer Symposium Meeting Abstracts. Available at: http://asco.org. Abstract 164.
103. Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002; 97: 393-399.
104. Rockwell P, Neufeld G, Classman A, Caron D, Goldstein N.In vitro neutralization of vascular endothelial growth factor activation Flk-1 by a monoclonal antibody. Mol Cell Differ 1995; 3: 91-109.
105. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787.
106. Mackey J, Gelmon K, Martin M, et al. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC- 1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer 2009, 9:258-261.
107. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-215.
108. Strumberg D. Preclinical and clinical development of the oral multikinase sorafenib in cancer treatment. Drugs Today (Barc) 2005; 41: 773-784.
109. Valabrega G, Capellero S, Cavalloni G, et al. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Res Treat 2011; 130: 29-40.
110. Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009; 27: 11-15.
111. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009; 20: 616-624.
112. Isaacs C, Herbolsheimer P, Liu MC, et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat 2011; 125: 137-143.
113. Baselga J, Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólido, Roché H, et al. SOLTI- 0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009; 69(Suppl): abstract 45.
114. Baselga J, Segalla JG, Roché H, et al. Sorafenib in combination with capecitabine: An oral regimen for patients with HER2- negative locally advanced or metastatic breast cancer. J Clin Oncol 2012; Mar 12. [Epub ahead of print]
115. Gradishar WJ, Kaklamani V, Prasad TS, et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer. Cancer Res 2009; 69(Suppl): abstract 44.
116. Gomez P, Roche H, Costa F, et al. Overall Survival Data from SOLTI-0701: A multinational, double-Blind, placebo-controlled, randomized phase 2b study evaluating the oral combination of sorafenib and capecitabine in patients with locally advanced or metastatic HER2-negative breast cancer. Cancer Res 2010; 70(Suppl.): 24 [Abstr P2-16-01].
117. Hudis C, Tauer KW, Hermann RC, et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol 2011; 29(Suppl.) [Abstr 1009].
118. Bondarde S, Kaklamani V, Prasad Sahoo T, et al. Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: Overall survival results from a double-blind, randomized, placebo-controlled, phase 2b trial. Cancer Res 2011, 70(Suppl.): 24 [Abstr P2-16-03]
119. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25: 884-896.
120. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
121. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010; 121: 121-131.
122. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010; 21: 1436-1441.
123. Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010; 21: 2370-2376.
124. Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010; 28(15S): abstract LBA1010.
125. Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010; 28(15S): abstract LBA1011.
126. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
127. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556.
128. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-793.
129. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006; 1: 1002-1009.
130. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11: 3369-3376.
131. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753-764.
132. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
133. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474-5483.
134. Rugo HS, Stopeck AT, Joy AA, et al. Randomized, placebocontrolled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011; 29: 2459-2465.
135. Kumar R, Knick VB, Rudolph SK et al. Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6: 2012-2021.
136. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15: 4220-4227.
137. Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer. J Clin Oncol 26: 2008; (May 20 suppl; abstr 1016).
138. Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010; 15(8): 810-8.
139. Fasolo A, Sessa C. MTOR inhibitors in the treatment of cancer. Expert Opin 2008; 17: 1717-34.
140. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13): 2278-2287.
141. Fasolo A, Gianni L, Rorive A, et al. Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. 2008 annual San Antonio Breast Cancer Symposium: Abstract 406.
142. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 125:447-455.
143. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 2010; 28: 5110-5115.
144. Macaskill EJ, Bartlett JM, Sabine VS, et al. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study. Breast Cancer Res Treat 2011; 128: 725-734.
145. von Minckwitz G, Eidtmann H, Loibl S, et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011; 22: 301-36.
146. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/ metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-4541.
147. Baselga J, Fumoleau P, Gil M. Phase II, 3 arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Preliminary results. J Clin Oncol 2004; 22(Suppl 14): 544.
148. Chow LWS, Sun Y, Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100(Suppl 1): 6091.
149. Romon R, Adriaenssens E, Lagadec C, et al. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 2010; 9: 157.
150. Adriaenssens E, Vanhecke E, Saule P, et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 2008; 68: 346-351.
151. Hassan S, Buchanan M, Jahan K, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 2011; 129: 225-232.
152. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 2009; 155: 231-236.
153. Richert MM, Vaidya KS, Mills CN, et al. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009; 21: 761-767.
154. Porvasnik S, Sakamoto N, Kusmartsev S, et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009; 69:1460-1469.
155. Wang N, Wang ZY, Mo SL, et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. Breast Cancer Res Treat 2012; Feb 21. [Epub ahead of print]
156. Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 2007; 97: 1372-1380.
157. Burstein HJ. Bevacizumab for advanced breast cancer: All tied up with a RIBBON? J Clin Oncol 2011; 29: 1232-1235.
158. Ratner M. Fearful of Avastin's fate, Genentech asks for unusual hearing. Nat Med 2011; 17: 233.
159. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
160. Boneberg EM, Legler DF, Hoefer MM, et al. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. Br J Cancer 2009; 101(4): 605-14.
161. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-9.
162. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-8.
163. Kim J, Vaziri S, Elson P, et al. VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 2009; 27: 15s, (suppl; abstr 5005).
164. Kim J, Vaziri S, Elson P, et al. Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib. J Clin Oncol 2010; 28: 15s, (suppl; abstract 4629).
165. Koutras A, Antonacopoulou A, Fostira F, et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. J Clin Oncol 2010; 28: 15s, (suppl; abstr 3587).
166. Lambrechts D, Delmar P, Buysschaert I, et al. VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumabtreated patients with metastatic pancreatic cancer. Eur J Cancer 2009; Supplements 7: 10
167. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297-302.
168. Zhang W, Dahlberg S, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009; 27: 15s, (suppl; abstr 8032).
169. Zhang W, Lee J, Schiller J, et al. Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small-cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501. J Clin Oncol 2010; 28: 15s, (suppl; abstr 7607).
170. Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity. Tissue Eng Part A 2010; 16: 1559-73.
171. Grimm D, Infanger M, Westphal K, et al. A delayed type of threedimensional growth of human endothelial cells under simulated weightlessness. Tissue Eng Part A. 2009; 15: 2267-75.